Determinants of in vitro drug susceptibility testing of Plasmodium vivax. - Wikidata - awgldk - TriplyDB

Determinants of in vitro drug susceptibility testing of Plasmodium vivax.

Determinants of in vitro drug susceptibility testing of Plasmodium vivax.

http://www.wikidata.org/entity/Q33313565

about

Comparative genomics of the neglected human malaria parasite Plasmodium vivax Antimalarial drug resistance: An overview Antimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertainties Targeting Plasmodium PI(4)K to eliminate malaria Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing Nonlinear mixed-effects modelling of in vitro drug susceptibility and molecular correlates of multidrug resistant Plasmodium falciparum Emerging Plasmodium vivax resistance to chloroquine in South America: an overview A novel multiple-stage antimalarial agent that inhibits protein synthesis Effective preparation of Plasmodium vivax field isolates for high-throughput whole genome sequencing Analysis of ex vivo drug response data of Plasmodium clinical isolates: the pros and cons of different computer programs and online platforms.Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia.Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria Resistance to therapies for infection by Plasmodium vivax Chloroquine efficacy studies confirm drug susceptibility of Plasmodium vivax in Chennai, India.In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax Pyronaridine: a new 'old' drug on the verge of entering the antimalarial armamentarium.KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission.Expression levels of pvcrt-o and pvmdr-1 are associated with chloroquine resistance and severe Plasmodium vivax malaria in patients of the Brazilian Amazon.Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis.Quinolone-3-diarylethers: a new class of antimalarial drug.Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P. vivax In vitro susceptibility of Plasmodium vivax to antimalarials in Colombia.Monitoring of clinical efficacy and in vitro sensitivity of Plasmodium vivax to chloroquine in area along Thai Myanmar border during 2009-2010.Methylene blue inhibits the asexual development of vivax malaria parasites from a region of increasing chloroquine resistance.Methotrexate is highly potent against pyrimethamine-resistant Plasmodium vivax.Molecular epidemiology of Plasmodium vivax anti-folate resistance in India.Chloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand.Histone methyltransferase inhibitors are orally bioavailable, fast-acting molecules with activity against different species causing malaria in humans In vitro anti-malarial drug susceptibility of temperate Plasmodium vivax from central China Analysis of chloroquine resistance transporter (CRT) isoforms and orthologues in S. cerevisiae yeast Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax.Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.Contrasting ex vivo efficacies of "reversed chloroquine" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates.Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax.

P2860

Q22122202-408D0C53-189B-43BD-AEB8-4A6947FFAA21 Q26753085-989279CE-96D1-4961-B554-B647A9291630 Q26866187-85B79917-06E9-4102-9DD8-48DECDD42C5D Q27974482-B95EDA2F-4860-445A-94B5-7B20575DFC35 Q28476754-B053698A-9F12-40DE-A7D0-4D0E7B2C544B Q28482113-47DB7951-36C8-4372-BC65-7028E7CBAD9F Q28534820-B1A071CE-E519-4880-A7FF-A88667368A32 Q28655984-969D4B52-3F9D-4520-A872-B7E38CB3636B Q30044020-14C18C6A-B83E-45A2-A66D-A107B7F2A6AF Q30459215-10AB2D0A-95E7-456C-BD2E-03FAE591E5BD Q30489045-C151A472-CDD0-4494-AB03-5CDDBD02668D Q33344900-DF24E6F1-3178-4615-8902-449F658A8E7A Q33371043-F04BD97B-EC81-42CF-9E4C-8A71C8526F1A Q33395221-9FE41D7A-956E-4FD1-8EEF-EAAFB748AD6F Q33419656-54A504DF-950C-4904-8CA0-979209AAAF5D Q33481576-12F425E0-D196-467E-BA8F-C92DCE2ACCF2 Q33612286-196CE44C-21FA-42C6-A5E0-6EA2875B226C Q33704762-A0753040-28DC-42F6-83A6-53F4D4B0837A Q33715256-661123E8-BCDF-437E-8891-3CFD9D9614EA Q33761137-049FE885-FDA2-40DF-9193-2311C01950F8 Q33764147-983D972E-FB3E-456B-A67B-69ABE4249E0E Q33876781-37BCEC24-7048-4DD2-8C96-381C070C1687 Q34057433-0CFED7A9-1E8F-400F-8BB5-B85CF94B17A6 Q34089944-3A06AC47-FDD3-432E-B3A2-479AD0230B5E Q34259032-12016A61-8478-4040-BAD2-A8BABEA96B23 Q34334269-9EB2638A-C153-4B71-8389-658B2E875C52 Q34360576-31723205-132D-4B8C-AE44-4CF7D5B0C9EB Q34596770-0420F628-3BE5-4875-9ED1-2AB28ED2BEC8 Q34660024-6E1CBE2E-39C2-49BE-8635-08549620F2AA Q34710568-AAA3DCC9-1D5A-4AC5-B5A0-49A3EFEC8DC3 Q34763470-B3E41577-6777-40F2-802F-E87D8861C113 Q34995136-685C0C30-501F-4316-9CCF-2369FFE9782A Q35038618-A9088740-F2ED-42E6-BFA9-E1ED43ED68A1 Q35105899-2A7062B2-074B-42CB-974B-E822F66FDEAD Q35131344-B2519FB9-6AB2-4BFE-A289-CD990BC72B7C Q35163958-FC7AB12B-1333-4CF4-B9C9-FF4E8BFDBE47 Q35191550-D09D524F-D56B-43AA-8E29-45712F811CB2 Q35191980-EA742D6D-0280-4655-94A6-99A528383CC9 Q35684833-DBB45570-57D5-405A-BF22-B46545315ED4 Q35701564-F642A6E6-A561-4304-B51D-9D9F683A999A

P2860

Determinants of in vitro drug susceptibility testing of Plasmodium vivax.

http://www.wikidata.org/entity/Q33313565

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Determinants of in vitro drug susceptibility testing of Plasmodium vivax.

@ast

Determinants of in vitro drug susceptibility testing of Plasmodium vivax.

@en

Determinants of in vitro drug susceptibility testing of Plasmodium vivax.

@nl

type

label

Determinants of in vitro drug susceptibility testing of Plasmodium vivax.

@ast

Determinants of in vitro drug susceptibility testing of Plasmodium vivax.

@en

Determinants of in vitro drug susceptibility testing of Plasmodium vivax.

@nl

prefLabel

Determinants of in vitro drug susceptibility testing of Plasmodium vivax.

@ast

Determinants of in vitro drug susceptibility testing of Plasmodium vivax.

@en

Determinants of in vitro drug susceptibility testing of Plasmodium vivax.

@nl

P1433

Q33313565-FD6BFB46-C95E-4225-BA49-22838030CE14

P1476

Q33313565-6BA0E459-1478-4ECE-AD13-74CA7A2FA4C1

P2093

Q33313565-2F5AB86A-93D5-4DFC-BC72-689774756D5A

Q33313565-4EDBD3A0-7601-4BFE-B5A6-20BAF3BE9834

Q33313565-4F9AAC74-2549-44E6-99F3-95C0ECB3CA04

Q33313565-60828888-C329-466A-8D79-0C659CFF1D65

Q33313565-7412F243-BD42-4AAE-8E37-BEA10E97BD69

Q33313565-754A4FCB-1F0E-4C27-95C7-BA62F5D9C196

Q33313565-A354FFDD-802A-4C1D-8455-2A4BCFA9850E

Q33313565-BA7C2511-6984-4E44-AAFB-91C6A5438780

Q33313565-D4A18ADA-7ACF-41AA-AC9F-33F7DF89187F

Q33313565-DAE51C70-E03C-4EEA-A445-53687620FC23

P2860

Q33313565-11E988A7-E581-4DF7-96FB-9415C86843FF

Q33313565-1B84A420-D697-4E1A-BB5B-1385A94A3F72

Q33313565-2E68488A-445C-4108-9989-E0AD3418EB17

Q33313565-443413A0-499E-4A3F-A9FA-D508858EE71B

Q33313565-454533D4-D2A9-4ED5-B94C-5E1CA8AC2CC1

Q33313565-46C00E57-C2C8-49AA-AFA8-3D2566171A40

Q33313565-46DE9395-A0D4-4CBE-93B9-D65E114AAE52

Q33313565-4E1DF462-0116-42DD-B4C8-55B1B237544B

Q33313565-505979CA-D0DB-4CC8-90DB-2BB5FBA1AB05

Q33313565-513DBF20-ACCC-4E78-8B62-A43087FADEA9

P304

Q33313565-B1B4A9B0-E394-497A-9907-35C1373FD273

P31

Q33313565-9A3FCC3A-C67E-4ADE-9FDA-AEB5BCEB98C0

P356

Q33313565-B52B79D1-B225-4E8F-AB33-186B10F789B5

P407

Q33313565-5E009355-5F0E-4A13-90AB-30B7F707D7BB

P433

Q33313565-6BF1BE48-FD67-4A6D-92DA-49A31B172EF4

P478

Q33313565-CCF04288-4ADD-49E4-9FDA-F75EF4C90592

P50

Q33313565-17DC8976-7ED9-4868-BBF8-538F42ECAB58

Q33313565-38B4F2AE-C859-495C-928E-4525181E4F74

Q33313565-4EBF4C1C-C747-4AC7-B31E-5CE086B2603F

P577

Q33313565-E8B7F38A-501B-42BD-A5B7-34A5EFC781F7

P698

Q33313565-7C999C34-59F2-4B69-A01E-9C1136C19950

P921

Q33313565-4841C746-F898-4206-A941-F53A1BCFBD23

P932

Q33313565-AF622643-6C54-498F-AC4D-D2539F1757CE

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Determinants of in vitro drug susceptibility testing of Plasmodium vivax.

@en

P2093

A Brockman

http://www.w3.org/2001/XMLSchema#string

B Prasetyorini

http://www.w3.org/2001/XMLSchema#string

E Kenangalem

http://www.w3.org/2001/XMLSchema#string

E Tjitra

http://www.w3.org/2001/XMLSchema#string

F Chalfein

http://www.w3.org/2001/XMLSchema#string

K Piera

http://www.w3.org/2001/XMLSchema#string

P Prayoga

http://www.w3.org/2001/XMLSchema#string

P Sugiarto

http://www.w3.org/2001/XMLSchema#string

Q Cheng

http://www.w3.org/2001/XMLSchema#string

R Suwanarusk

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic responses to different antimalarial drugs in vivax malaria

Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua.

Chloroquine-resistant Plasmodium vivax in transmigration settlements of West Kalimantan, Indonesia.

Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia.

Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia.

Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals.

Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.

Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms.

Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels.

In vitro efficacy of antimalarial drugs against Plasmodium vivax on the western border of Thailand.

P304

1040-1045

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01334-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas M Anstey

P577

2008-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18180357

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium vivax

P932

2258486

http://www.w3.org/2001/XMLSchema#string